This is a single-center, non-randomized, single-arm, open-label study, in which adults with episodic or chronic migraine will receive intravenous infusion with calcitonin gene-related peptide and subsequently be treated with erenumab. The study will consist of the following elements:~Provocation Phase (1 experimental day with intravenous infusion of calcitonin gene-related peptide)~Screening/Baseline Phase (4 weeks)~Open-Label Treatment Phase (24 weeks)
To explore the relationship between clinical response to erenumab and response to intravenous infusion of calcitonin gene-related peptide in individuals with migraine.